Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | JAB-8263 |
Synonyms | |
Therapy Description |
JAB-8263 is a BET inhibitor that that binds BRD2, BRD3, BRD4, and BRDT and prevents their interaction with acetylated histones, thereby leading to altered chromatin modeling and gene expression patterns, and potentially resulting in inhibition of tumor cell growth (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JAB-8263 | JAB8263|JAB 8263 | BET Inhibitor (Pan) 32 | JAB-8263 is a BET inhibitor that that binds BRD2, BRD3, BRD4, and BRDT and prevents their interaction with acetylated histones, thereby leading to altered chromatin modeling and gene expression patterns, and potentially resulting in inhibition of tumor cell growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04587479 | Phase I | JAB-8263 | A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors | Unknown status | USA | 0 |